<VariationArchive RecordType="classified" VariationID="583663" VariationName="NC_000022.11:g.(?_38169198)_(38169446_?)del" VariationType="Deletion" Accession="VCV000583663" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-05-24" DateCreated="2019-08-13" MostRecentSubmission="2019-08-13">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="575208" VariationID="583663">
      <GeneList>
        <Gene Symbol="PLA2G6" FullName="phospholipase A2 group VI" GeneID="8398" HGNC_ID="HGNC:9039" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38111495" stop="38181830" display_start="38111495" display_stop="38181830" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38507501" stop="38577835" display_start="38507501" display_stop="38577835" Strand="-" />
          </Location>
          <OMIM>603604</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000022.11:g.(?_38169198)_(38169446_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" innerStart="38169198" innerStop="38169446" display_start="38169198" display_stop="38169446" variantLength="249" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" innerStart="38565205" innerStop="38565453" display_start="38565205" display_stop="38565453" variantLength="249" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.(?_38565205)_(38565453_?)del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.(?_38565205)_(38565453_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.(?_38169198)_(38169446_?)del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.(?_38169198)_(38169446_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000022.11:g.(?_38169198)_(38169446_?)del AND Infantile neuroaxonal dystrophy" Accession="RCV000707946" Version="2">
        <ClassifiedConditionList TraitSetID="1718">
          <ClassifiedCondition DB="MedGen" ID="C0270724">Infantile neuroaxonal dystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-10-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-10-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-13" MostRecentSubmission="2019-08-13">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Infantile neuroaxonal dystrophy 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seitelberger disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
                <XRef ID="Neuroaxonal+dystrophy%2C+infantile/5159" DB="Genetic Alliance" />
                <XRef ID="52713000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">INAD1</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">INAD</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C0270724" DB="MedGen" />
              <XRef ID="MONDO:0024457" DB="MONDO" />
              <XRef Type="MIM" ID="256600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1609081" SubmissionDate="2019-03-28" DateLastUpdated="2019-08-13" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="4474865|MedGen:C0270724" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000837056" DateUpdated="2019-08-13" DateCreated="2018-10-10" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-10-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon 2 of the PLA2G6 gene, which includes the initiator codon. The 5' end of this event is unknown as it extends beyond the assayed region for this gene and therefore may encompass additional genes. The 3' boundary is likely confined to intron 2 of the PLA2G6 gene. This is expected to result in an absent or disrupted protein product. This variant has not been reported in the literature in individuals with PLA2G6-related disease. Loss-of-function variants in PLA2G6 are known to be pathogenic (PMID: 16783378, 18570303, 18799783, 22213678). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.(?_38565205)_(38565453_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0270724" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1609081" TraitType="Disease" MappingType="Name" MappingValue="Infantile neuroaxonal dystrophy" MappingRef="Preferred">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

